Analyst Price Targets — CYTK
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| March 6, 2026 12:51 pm | Ashwani Verma | UBS | $69.00 | $60.59 | StreetInsider | Cytokinetics (CYTK) PT Raised to $69 at UBS Amid Improved nHCM Outlook |
| February 20, 2026 1:27 pm | — | RBC Capital | $101.00 | $68.13 | TheFly | Cytokinetics price target raised to $101 from $95 at RBC Capital |
| February 3, 2026 1:10 pm | Srikripa Devarakonda | Truist Financial | $92.00 | $66.47 | TheFly | Cytokinetics price target raised to $92 from $84 at Truist |
| January 9, 2026 12:52 pm | Akash Tewari | Jefferies | $90.00 | $63.24 | StreetInsider | Cytokinetics (CYTK) PT Raised to $90 at Jefferies |
| January 8, 2026 12:45 pm | Maxwell Skor | Morgan Stanley | $90.00 | $65.25 | TheFly | Cytokinetics price target raised to $90 from $71 at Morgan Stanley |
| December 22, 2025 5:43 pm | Srikripa Devarakonda | Truist Financial | $84.00 | $67.33 | TheFly | Cytokinetics price target raised to $84 from $70 at Truist |
| December 22, 2025 5:40 pm | — | Morgan Stanley | $71.00 | $67.39 | TheFly | Cytokinetics price target raised to $71 from $65 at Morgan Stanley |
| December 22, 2025 4:39 pm | Roanna Ruiz | Leerink Partners | $83.00 | $68.46 | TheFly | Cytokinetics price target raised to $83 from $73 at Leerink |
| December 22, 2025 12:43 pm | — | RBC Capital | $95.00 | $62.72 | TheFly | Cytokinetics price target raised to $95 from $87 at RBC Capital |
| December 22, 2025 12:25 pm | Serge Belanger | Needham | $84.00 | $69.25 | StreetInsider | Cytokinetics (CYTK) PT Raised to $84 at Needham |
Latest News for CYTK
Fisher Asset Management LLC lifted its stake in shares of Cytokinetics, Incorporated (NASDAQ: CYTK) by 3.8% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 761,587 shares of the biopharmaceutical company's stock after acquiring an additional 27,907 shares during the
SOUTH SAN FRANCISCO, Calif., March 02, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that members of the Company management team will participate in the following investor conferences in March: Leerink 2026 Global Healthcare Conference: Fireside chat on Monday, March 9, 2026 at 9:20 AM Eastern Time in Miami Beach, FL.
CYTK reports a wider-than-expected Q4 loss as expenses rise, but Myqorzo wins FDA nod and global expansion advances, with $1.22B cash fueling 2026 catalysts.
Cytokinetics, Incorporated (CYTK) Q4 2025 Earnings Call Transcript
Cytokinetics (CYTK) came out with a quarterly loss of $1.5 per share versus the Zacks Consensus Estimate of a loss of $1.48. This compares to a loss of $1.26 per share a year ago.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for CYTK.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.